Breaking News:Study finds two approaches for treating heart valve patients – The South First– What Just Happened

Heart valve disease in India presents a unique challenge because two very different patient groups are affected.

Synopsis: The study monitored 1,000 patients with severe symptomatic aortic stenosis, comparing those who underwent TAVR — where doctors replace the valve using a thin tube inserted through a blood vessel — with patients who had conventional open-heart surgery.

As India faces a rising burden of valve disorders affecting both younger adults and the elderly, new global research has suggested that two major treatment approaches may offer similarly durable results.

A study published in The New England Journal of Medicine tracked patients with severe aortic stenosis — a condition where the heart’s aortic valve narrows and restricts blood flow — for seven years.

The research compared outcomes between a minimally invasive procedure called Transcatheter Aortic Valve Replacement (TAVR) and traditional open-heart surgical valve replacement.

The findings offered important guidance for India, where doctors are increasingly treating valve disease in younger patients.

Also Read: Study reveals 80% Indians face cardiac risks

The findings

The study monitored 1,000 patients with severe symptomatic aortic stenosis, comparing those who underwent TAVR — where doctors replace the valve using a thin tube inserted through a blood vessel — with patients who had conventional open-heart surgery.

“Both treatment strategies showed similar long-term outcomes over seven years,” the study said. It indicated that patients in both groups had comparable survival and health results.

The combined rate of death, stroke or heart-related rehospitalisation was 34.6% in the TAVR group and 37.2% in the surgery group, which the researchers said was “not statistically significant.”

More than 73% of patients in both groups were alive and free of valve failure seven years after the procedure. The study also noted that “the durability of the implanted valves remained strong in both treatment groups,” suggesting that either option can provide lasting benefits.

Looking at individual outcomes, death rates were 19.5% in the TAVR group compared with 16.8% among surgery patients. Stroke rates were almost identical — 8.5% for TAVR and 8.1% for surgery — while rehospitalisation rates were 20.6% and 23.5% respectively.

“In India, we are no longer just managing valve disease, we are planning for a patient’s entire cardiac future,” said Dr Praveen Chandra, Chairman of Interventional Cardiology at Medanta, Gurugram.

“This data gives us meaningful confidence that both approaches can deliver sustained benefit,” he added.

Also Read: Vitamin D deficiency linked to six-fold increase in heart disease risk

Why the findings matter for India

Heart valve disease in India presents a unique challenge because two very different patient groups are affected. Rheumatic heart disease, caused by untreated infections that damage heart valves, still affects many younger people in rural and semi-urban areas.

At the same time, hospitals in major cities are reporting increasing cases of degenerative aortic stenosis — the age-related valve disease more commonly seen in Western countries.

The study highlighted that India now faces “a dual cardiac burden driven by rheumatic disease in younger adults and degenerative valve disease in ageing populations.”

Rheumatic heart disease occurs when untreated throat infections lead to permanent damage to heart valves. Estimates suggest that between 1.5 and 2 per 1,000 Indians are affected, with more than two million people living with the condition.

For cardiologists, the age factor is crucial. “Indian patients are often younger when they require their first valve replacement compared with Western populations,” the study noted.

Dr Chandra said this makes treatment decisions more complex. “The first valve decision needs to be made carefully, with the next 20 to 30 years in mind, not just the procedure itself,” he said.

Also Read: One in three Kerala adolescents pre-diabetic

Differences between procedures

While overall outcomes were similar, the study found important differences between the two treatment approaches.

One notable difference was the risk of atrial fibrillation — an irregular heart rhythm that can increase the risk of stroke. The authors reported that “new-onset atrial fibrillation occurred more frequently after surgical valve replacement.”

Specifically, 43.5% of patients who underwent open-heart surgery developed the condition compared with 17.7% of those treated with TAVR.

However, the study also found that pacemaker implantation — a device used to regulate heart rhythm — was more common among patients who underwent the minimally invasive procedure.

“Pacemaker implantation occurred in 17.3% of the TAVR group compared with 12.8% in the surgery group,” the researchers wrote.

These differences can influence treatment choices, particularly in India, where access to follow-up care and monitoring may vary between urban hospitals and smaller centres.

Also Read: How India is missing congenital heart diseases

A shift toward lifelong cardiac planning

Experts said the study reinforced the need to think about valve replacement as part of long-term care rather than a single procedure.

The authors emphasised that “valve replacement marks the beginning of a long treatment journey rather than the endpoint.”

As procedures like TAVR become more widely available in India, doctors are increasingly focusing on long-term strategies for patients who may live decades after their first intervention.

Dr Chandra said this shift is already shaping clinical practice. “What we are seeing now is a move from procedure-focused care to lifetime planning for valve disease patients,” he said.

The study also reported encouraging quality-of-life outcomes. Nearly three-quarters of participants were alive with mild or no heart failure symptoms seven years after their procedure.

The researchers noted that “timely intervention and appropriate treatment planning can significantly improve long-term outcomes.”

A final 10-year analysis of the study is expected in the coming years and will be closely watched by cardiologists worldwide. For India, where millions live with undiagnosed or untreated valve disease, the findings offer reassurance that both treatment approaches can deliver lasting results.

(Edited by Majnu Babu).